BusinessDrug Master File for Prostate Imaging Product Filed with the FDABy Nasdaq OMXMar 26, 2018, 12:00 PM UTC
BusinessExosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical AffairsBy Nasdaq OMXMar 21, 2018, 11:41 AM UTC
BusinessExosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United StatesBy Nasdaq OMXFeb 23, 2018, 12:47 PM UTC
BusinessExosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMedBy Nasdaq OMXFeb 1, 2018, 12:35 PM UTC
BusinessExosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the USBy Nasdaq OMXJan 25, 2018, 12:30 PM UTC
BusinessHIFU for Prostate Cancer Now Available at Chesapeake UrologyBy Nasdaq OMXJan 23, 2018, 3:00 PM UTC
BusinessOTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference ParticipantsBy Nasdaq OMXJan 11, 2018, 6:39 PM UTC
BusinessExosome Diagnostics Announces Positive Coverage for EPI from Largest Payor in the Mid-Atlantic RegionBy Nasdaq OMXJan 8, 2018, 6:15 PM UTC
